@article {TzilasPA4733, author = {Vasilios Tzilas and Argyrios Tzouvelekis and Evangelos Bouros and Matthew Katsaras and Maria Ntassiou and Theodoros Karampitsakos and Demosthenes Bouros}, title = {Antifibrotic treatment in 18 patients with chronic Hypersensitivity Pneumonitis}, volume = {54}, number = {suppl 63}, elocation-id = {PA4733}, year = {2019}, doi = {10.1183/13993003.congress-2019.PA4733}, publisher = {European Respiratory Society}, abstract = {Introduction: Chronic Hypersensitivity Pneumonitis (c-HP) can exhibit an IPF-like course despite immunosuppressive treatment. In this group of patients there is a need for new therapeutic approaches.Aim: To investigate the effect of antifibrotics in the clinical course of c-HP.Patients and Methods: Retrospective analysis of patients with an initial diagnosis of IPF that were subsequently diagnosed as c-HP in the context of multidisciplinary discussion (Jan2012-Dec2016). HP diagnosis was based in the absence of alternative diagnoses when at least two of the following criteria were present: Recognition of an inciting antigen, compatible HRCT pattern (mainly presence of mosaic pattern), BAL lymphocytosis\>20\%.Results: We enrolled in the study 96 patients with HP. From this cohort we identified 18 patients, initially diagnosed as IPF (16 males, 88,9\%, median age 70 years (95\% CI for the median 63 to 73.6) that had received antifibrotics for at least 12 months (10 pirfenidone and 8 nintedanib). Mean ({\textpm}SE) relative changes in \%FVCpred and \%DLcopred over one year was -4.19{\textpm}3.29 and -5.72{\textpm}5.32, respectively. A decline in FVC was observed in 11 patients (in 4 patients \> 10\%, and in 5 patients between 5-10\%). An increase in relative \%FVCpred was observed in 7 patients (mean ΔFVC {\textpm} SE = 8.69{\textpm}3.75).Conclusions: Antifibrotics can stabilize FVC decline in patients with c-HP. Large randomized trials are needed.FootnotesCite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4733.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/54/suppl_63/PA4733}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }